Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2017-07 Issue:7 Volume:18 Page:904-916
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Baselga José,Im Seock-Ah,Iwata Hiroji,Cortés Javier,De Laurentiis Michele,Jiang Zefei,Arteaga Carlos L,Jonat Walter,Clemons Mark,Ito Yoshinori,Awada Ahmad,Chia Stephen,Jagiełło-Gruszfeld Agnieszka,Pistilli Barbara,Tseng Ling-Ming,Hurvitz Sara,Masuda Norikazu,Takahashi Masato,Vuylsteke Peter,Hachemi Soulef,Dharan Bharani,Di Tomaso Emmanuelle,Urban Patrick,Massacesi Cristian,Campone Mario

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Comprehensive molecular portraits of human breast tumours;Nature,2012

2. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014

3. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer;Baselga;N Engl J Med,2012

4. Palbociclib in hormone-receptor-positive advanced breast cancer;Turner;N Engl J Med,2015

5. Molecular portraits of human breast tumours;Perou;Nature,2000

Cited by 442 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flurbiprofen clubbed schiff's base derivatives as potent anticancer agents: In Vitro and In Silico approach towards breast cancer;Journal of Molecular Structure;2025-02

2. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

3. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

4. Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA;Advanced Materials;2024-08-15

5. Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-10